Erlotinib (Tarceva ®)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
Cancer. 2008 Jun 9. [Epub ahead of print] [Link] Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Danaâ€Farber Cancer Institute, Boston, Massachusetts. Abstract Background: We conducted a phase 2, multicenter, open-label study of erlotinib plus bevacizumab in patients with malignant pleural mesothelioma who…
Read MorePhase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study
Journal of Clinical Oncology. 2007 Jul 15;110(2):420-31. [Link] Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. University of Arizona Cancer Center, Tucson, AZ, USA. Abstract Purpose:Malignant pleural mesothelioma (MPM) expresses high levels of epidermal growth factor receptor (EGFR), and preclinical studies have identified…
Read MoreBiology and management of malignant pleural mesothelioma
European Journal of Cancer. 2006 Sep 19; [Epub ahead of print] [Link] Paolo A. Zucali1, a and Giuseppe Giacconea aDepartment of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands Received 18 July 2006; accepted 19 July 2006. Available online 20 September 2006. Abstract Malignant mesothelioma is an aggressive tumour,…
Read More